Search

Your search keyword '"Cazzola, Mario"' showing total 158 results

Search Constraints

Start Over You searched for: Author "Cazzola, Mario" Remove constraint Author: "Cazzola, Mario" Database OpenAIRE Remove constraint Database: OpenAIRE
158 results on '"Cazzola, Mario"'

Search Results

1. Novel Anti-Inflammatory Approaches to COPD

2. Beyond Dual Bronchodilation – Triple Therapy, When and Why

3. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

4. Combined burden and functional impact tests for cancer driver discovery using DriverPower

5. Integrative pathway enrichment analysis of multivariate omics data

6. Pathway and network analysis of more than 2500 whole cancer genomes

7. Divergent mutational processes distinguish hypoxic and normoxic tumours

8. Genomic footprints of activated telomere maintenance mechanisms in cancer

10. Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile

11. Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease

12. Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy

13. Bronchodilators in bronchiectasis: there is light but it is still too dim

14. An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease

15. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (Nature Medicine, (2020), 26, 10, (1549-1556), 10.1038/s41591-020-1008-z)

16. New Avenues for Phosphodiesterase Inhibitors in Asthma

17. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (Nature Medicine, (2020), 26, 10, (1549-1556), 10.1038/s41591-020-1008-z)

18. Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis

19. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)

20. Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease

21. Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple therapy in COPD

22. Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review

23. Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review

25. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation

26. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

27. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology

28. Additional file 1: of Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways

29. Doxofylline is not just another theophylline!

30. The European Hematology Association Roadmap for European Hematology Research: a consensus document

31. GLP1-R: a Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness

32. Acute exacerbations of COPD: risk factors for failure and relapse

33. The U2AF1S34F mutation induces lineage-specific splicing 1 alterations in myelodysplastic syndromes

34. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera

35. PROGRESS AND PROSPECTS FOR LONG-ACTING β2-AGONISTS IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

36. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

37. Airflow obstruction: is it asthma or is it COPD?

38. Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF

39. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

40. Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease

41. Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol

42. Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety

43. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

44. Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life

45. A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges

46. Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

47. The clinical use of regenerative therapy in COPD

48. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis

49. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol

50. Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists

Catalog

Books, media, physical & digital resources